Should You Invest in ATAI Life Sciences N.V. (ATAI) Now?

The 36-month beta value for ATAI is at 0.97. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for ATAI is 115.36M, and currently, shorts hold a 4.51% of that float. The average trading volume for ATAI on April 03, 2024 was 1.52M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

ATAI) stock’s latest price update

ATAI Life Sciences N.V. (NASDAQ: ATAI)’s stock price has increased by 19.79 compared to its previous closing price of 1.87. However, the company has seen a 29.48% increase in its stock price over the last five trading sessions. Proactive Investors reported 2024-03-28 that atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its operations into 2026 as it continues to advance psychedelic-based therapies targeting several mental health conditions. Recent clinical highlights included positive results from Beckley Psytech’s Phase 2a study of BPL-003, an intranasal formulation of 5-MeO-DMT, in patients with treatment-resistant depression.

ATAI’s Market Performance

ATAI’s stock has risen by 29.48% in the past week, with a monthly rise of 7.18% and a quarterly rise of 32.54%. The volatility ratio for the week is 9.16% while the volatility levels for the last 30 days are 8.77% for ATAI Life Sciences N.V. The simple moving average for the last 20 days is 21.97% for ATAI stock, with a simple moving average of 39.86% for the last 200 days.

Analysts’ Opinion of ATAI

Loop Capital, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $18. The rating they have provided for ATAI stocks is “Buy” according to the report published on November 01st, 2022.

Maxim Group gave a rating of “Buy” to ATAI, setting the target price at $25 in the report published on November 30th of the previous year.

ATAI Trading at 21.66% from the 50-Day Moving Average

After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.28% of loss for the given period.

Volatility was left at 8.77%, however, over the last 30 days, the volatility rate increased by 9.16%, as shares surge +4.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.11% upper at present.

During the last 5 trading sessions, ATAI rose by +21.10%, which changed the moving average for the period of 200-days by +17.04% in comparison to the 20-day moving average, which settled at $1.8407. In addition, ATAI Life Sciences N.V. saw 58.87% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ATAI starting from Brand Florian, who purchase 20,000 shares at the price of $1.16 back on Nov 16 ’23. After this action, Brand Florian now owns 130,000 shares of ATAI Life Sciences N.V., valued at $23,120 using the latest closing price.

Brand Florian purchase 40,000 shares at $1.45 during a trade that took place back on Sep 13 ’23, which means that Brand Florian is holding 110,000 shares at $57,968 based on the most recent closing price.

Stock Fundamentals for ATAI

Current profitability levels for the company are sitting at:

  • -397.42 for the present operating margin
  • -0.71 for the gross margin

The net margin for ATAI Life Sciences N.V. stands at -128.7. The total capital return value is set at -0.46. Equity return is now at value -15.97, with -13.43 for asset returns.

Based on ATAI Life Sciences N.V. (ATAI), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.38. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -46.97.

Currently, EBITDA for the company is -125.15 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 1093.44. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.22.

Conclusion

In conclusion, ATAI Life Sciences N.V. (ATAI) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts